detalimogene voraplasmid ("detalimogene") — Topline data
2H 2026
Enrollment Complete: 12-Month Data Update Expected 2H 2026Source filing
ENGN biotech catalysts & pipeline
ENGENE THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
detalimogene voraplasmid ("detalimogene") — FDA meeting
2H 2026
Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026Source filing
detalimogene voraplasmid ("detalimogene") — NDA/BLA submission
2H 2026
$285M in Cash; Pivotal Cohort 12-month Data and Filing of BLA Expected in 2H 2026Source filing
detalimogene voraplasmid ("detalimogene") — Regulatory decision
2027
Pivotal cohort 12-month data and filing of BLA expected in 2H 2026, and potential approval and platform designation 2027Source filing